
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate Inc, a clinical-stage biopharmaceutical company, operates within a growing market, with total ADHD medication sales in the U.S. expanding approximately 8% annually, reaching around $18 billion in 2020. The company’s proprietary precision timed-release drug delivery platform shows promise, as evidenced by positive topline results from its CTx-1301 trial, indicating a favorable effect on subjects compared to placebo. These developments suggest significant upside potential for Cingulate's stock, positioning the company to capitalize on robust market demand while mitigating associated risks through innovative product offerings.
Bears say
Cingulate Inc reported a net loss of $4.8 million, translating to an earnings per share (EPS) of $(1.09), which exceeded both the company's estimates of $(0.90) and the consensus estimate of $(0.87), highlighting a worse-than-expected financial performance. The company faces multiple significant risks that could impede its growth, including liquidity challenges, potential failures in demonstrating the safety and efficacy of its product candidates during clinical trials, and hurdles in obtaining necessary regulatory approvals. Additionally, competitive pressures and varying investor sentiment towards the biotech sector further complicate Cingulate's ability to capitalize on its proprietary drug delivery platform and achieve commercial success.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares